SPECT study of regional cerebral perfusion in neuroleptic-resistant schizophrenic patients who responded or did not respond to clozapine

American Journal of Psychiatry

Volumn 153, Issue 10, 1996, Pages 1343-1346

  Molina Rodríguez, Vicente ^a   Andreé, Richard Montz ^b   Jesus Perez Castejon M ^b   Capdevila García, Ernesto ^b   Carreras Delgado, J Luis ^b   Rubia Vila, José ^b  

^a INSTITUTO PLURIDISCIPLINAR   (Spain)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT;

ADULT; ARTICLE; BRAIN CORTEX; BRAIN PERFUSION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG RESPONSE; HUMAN; PREDICTION; PREFRONTAL CORTEX; PRIORITY JOURNAL; SCHIZOPHRENIA;

EID: 0345596216     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/ajp.153.10.1343     Document Type: Article

References (18)

1. Lieberman JA, Kane JM, Safferman AZ, Pollack S, Howard A, Szymansky S, Magiar SJ, Kronig MH, Cooper T, Novacenteo H: Predictors of response to clozapine. J Clin Psychiatry 1994; 55 (Sept suppl B):126-128
2. Friedman L, Knutson L, Shurell M, Meltzer HY: Prefrontal sulcal prominence is inversely related to response to clozapine in schizophrenia. Biol Psychiatry 1991; 29:865-877
3. Andreasen NC: Scale for the Assessment of Positive Symptoms (SAPS). Iowa City, University of Iowa, 1983
4. Andreasen NC: Scale for the Assessment of Negative Symptoms (SANS). Iowa City, University of Iowa, 1983
5. Guy W (ed): ECDEU Assessment Manual for Psychopharmacology: Publication ADM 76-338. Rockville, Md, US Department of Health, Education, and Welfare, 1976, pp 217-222
6. Nieuwenhuys R, Voogd J, Van Huizen C: The Human Central Nervous System: A Synopsis and Atlas, 3rd ed. New York, Springer-Verlag, 1988
7. Molina V, Montz R, Martín-Loeches M, Jiménez-Vicioso A, Carreras JL, Rubia FJ: Drug therapy and cerebral perfusion in obsessive-compulsive disorder. J Nucl Med 1995; 36:2234-2238
8. Buchsbaum MS, Potkin SG, Siegel BV, Lottenberg S, Marshall J, Bunney WE: Striatal metabolic rate and clinical response to neuroleptics in schizophrenia. Arch Gen Psychiatry 1992; 49: 966-974
9. Farde L, Nordström A, Wiesel F, Pauli S, Halldin C, Sedvall G: Positron emission tomographic analysis of central D1 and D2 receptor occupancy in patients treated with classical neuroleptics and clozapine. Arch Gen Psychiatry 1992; 49:538-544
10. Buchsbaum MS, Potkin SG, Marshall JF, Siegel BV, Lohr J, Kartz M, Gottschalk LA, Gulase Karam B, Marshall J, Lottenberg S, Teng CY, Abel L, Bunney WE: Effects of clozapine and thiothixene on glucose metabolic rate in schizophrenia. Neuropsychopharmacology 1992; 6:155-163
11. Liddle PF, Friston KJ, Frith CD, Hirsch SR, Jones T, Frackowiak RSJ: Patterns of cerebral blood flow in schizophrenia. Br J Psychiatry 1992; 160:179-186
12. Breier A: Clozapine and noradrenergic function: support for a novel hypothesis for superior efficacy. J Clin Psychiatry 1994; 55(Sept suppl B):122-125
13. Moore RY, Bloom FE: Central catecholamine neuron systems: anatomy and physiology of the norepinephrine and epinephrine systems. Annu Rev Neurosci 1979; 2:113-168
14. Tassin JP, Trovero F, Herve D: Biochemical and behavioral consequences of interactions between dopaminergic and noradrenergic systems in rat prefrontal cortex. Neurochem Int 1992; 20: 225S-230S
15. Lundberg T, Lindstrom LH, Hartvig P: Striatal and frontal cortex binding of 11C-labelled clozapine visualized by positron emission tomography (PET) in drug-free schizophrenics and healthy volunteers. Psychopharmacology (Berl) 1989; 99:8-12
16. Van Tol HH, Bunzow JR, Guan HC, Sunahara RK, Seeman P, Niznik HB, Civelli O: Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature 1991; 350:610-614
17. Niznik HB, Van Tol HHM: Dopamine receptor genes: new tools for molecular psychiatry. J Psychiatry Neurosci 1992; 17:158-180
18. Alexander GE, Crutcher MD: Functional architecture of basal ganglia circuits: neuronal substrates of parallel processing. Trends Neurosci 1990; 13:266-271